Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biotechnology company Alkermes and Indevus Pharmaceuticals have reported positive results from a randomized, double-blind, placebo controlled Phase IIa clinical study of a drug for chronic obstructive pulmonary disease.
Subscribe to our email newsletter
ALKS 27 is an inhaled formulation of trospium chloride, a muscarinic receptor antagonist that relaxes smooth muscle tissue and has the potential to improve airflow in patients with chronic obstructive pulmonary disease (COPD).
Elliot Ehrich, CMO of Alkermes, said: “These preliminary data are encouraging and suggest that ALKS 27 may have several key attributes, including daily administration, rapid onset of action and prolonged duration of bronchodilation that could enhance clinical outcomes for COPD patients.”
Glenn Cooper, chairman and CEO of Indevus, said: “The results of this trial demonstrate that ALKS 27 has the potential to offer patients a new option in the treatment of COPD, a large and underserved disease affecting millions of people each year. Based on these positive results, we are moving forward with Alkermes to identify a partner for the future development and commercialization of ALKS 27.”